TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03684018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: Normal human immunoglobulin G administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: Normal human immunoglobulin G administered intravenously
Study: NCT00413153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir/ritonavir
Description: atazanavir 300mg + ritonavir 100mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir
Description: patient remains on their pre-study dose of lopinavir/ritonavir
Study: NCT00794573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
Study: NCT03705169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR441236
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR441236
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR441236
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
Study: NCT02555059

Intervention type: DRUG
Intervention: Cipro (Ciprofloxacin, BAYQ3939)
Description: Treatment parameters following the physician's decision based on the summary of product characteristics.
Study: NCT01879800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy plus Illness Management
Study: NCT04598672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTi)
Description: Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
Study: NCT01091376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg/day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: 60-70Gy/30-35f
Study: NCT02344134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607
Description: 0.5 mL, intramuscular, a single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal S1
Description: 0.5 mL, intramuscular, a single dose
Study: NCT02431884

Intervention type: PROCEDURE
Intervention: collect body fluids/tissues & med history
Description: collect tissues/fluids \& history
Study: NCT03951870

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation via fMRI Neurofeedback task
Description: Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromodulation via fMRI Neurofeedback task
Description: Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccination
Description: Subjects will be vaccinated against Hepatitis B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination
Description: Subjects will be vaccinated against Hepatitis B

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B vaccination
Description: Subjects will be vaccinated against Hepatitis B
Study: NCT03156270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivaer Stylus
Description: Stylus used to deliver low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
Study: NCT03209830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSU 6162
Description: All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
Study: NCT03998085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
Study: NCT03719183

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional Cytogenetics Studies
Description: Metaphase cytogenetic studies will be performed in all cases according to standard methods. Chromosome preparations will be G-banded using trypsin and Giemsa, and karyotypes will be described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2016.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescent in Situ Hybridization (FISH) Panels
Description: AML Panel includes:~* t(8;21) (RUNX1-RUNX1T1).~* inv(16), t(16;16) (CBFB-MYH11).~* t(9;22) (BCR-ABL).~* 11q23 KMT2A rearrangements.~* inv(3) MECOM rearrangements.~* DEK-NUP214 rearrangements.~* Del(5q) Deletion~* Del(7q) Deletion~Acute Promyelocytic Leukemia panel includes:~* t(15;17) (PML-RARA).~* 17q RARA rearrangements

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiplex FISH (M-FISH)
Description: 24-color karyotyping
Study: NCT00096382

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: aldesleukin
Description: high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: aldesleukin
Description: high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Description: 10 mcg/kg/day daily subcutaneously until neutrophil count \>1x10\^9/1.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Description: 10 mcg/kg/day daily subcutaneously until neutrophil count \>1x10\^9/1.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: therapeutic tumor infiltrating lymphocytes
Description: Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: therapeutic tumor infiltrating lymphocytes
Description: Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenously over 1 hour

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenously over 1 hour

Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine phosphate
Description: 25 mg/m\^2/day intravenous piggyback daily over 15-20 minutes for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine phosphate
Description: 25 mg/m\^2/day intravenous piggyback daily over 15-20 minutes for 5 days

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
Study: NCT04174599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-627
Description: Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: F-627
Description: Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein
Study: NCT01931436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qing'E pill
Description: Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
Study: NCT03447925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal Plant
Description: Medicinal Plant Extract with vaseline cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal Plant
Description: Medicinal Plant Extract with vaseline cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salicylate
Description: Salicylate 10% with vaseline cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaseline
Description: Vaseline cream
Study: NCT02447211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxepin cream 5%
Description: Patients use doxepin creamtwice daily for one weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients use cream without doxepin ingredient twice daily for one weeks
Study: NCT02614326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autobiographical Memory Flexibility (MemFlex) training
Description: As in experimental arm description

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: As in experimental arm description
Study: NCT03525405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: napabucasin
Description: Single 240 mg dose containing 100 μCi of 14C-napabucasin will be administered with 240 mL of water following an overnight fast.
Study: NCT02838823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody toripalimab
Description: humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Study: NCT03252535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellavita HD lower dose
Description: The participants will receive a total of 9 intravenous administrations of 1x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellavita HD higher dose
Description: The participants will receive a total of 9 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
Study: NCT03187483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic treatment
Description: orthodontic treatment in maxillary crowding

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic treatment
Description: orthodontic treatment in maxillary crowding
Study: NCT02808806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: real-time audio-visual feedback
Description: real-time audio-visual feedback to caregivers on TSD (i.e. displaying time, a colour code which will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded, and auditory signals indicating the elapsed time), displayed through handhelds and on pre-mounted tablets through the whole trajectory of acute stroke care
Study: NCT01208402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
Study: NCT01757769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: 8 mg daily for 24 weeks
Study: NCT01169467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care plus Dexmedetomidine
Description: Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-Care
Description: Subjects who are treated with the standard of care sedation regiment only.
Study: NCT01208402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
Study: NCT02479412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 μg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 μg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 μg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 μg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 μg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 μg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Study: NCT03252535

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
Study: NCT02479412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 µg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 µg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Study: NCT01505595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: 12 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham proprioceptive training
Description: Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
Study: NCT01186783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivabradine
Description: Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.~Day 1 and 2:~5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)~Day 3 and 4:~5,0 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm (acute renal failure: 70bpm≥heart rate \<90bpm~7,5 mg ivabradine b.i.d. if heart rate ≥90bpm
Study: NCT01499927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electronic reminders
Description: Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
Study: NCT02997956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Chemoembolization
Description: Minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
Study: NCT02891564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Band Together
Description: a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms. This game is analogous to Project: EVO.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Mobile 3D video game
Description: expectancy-matched control game
Study: NCT03787108

Intervention type: OTHER
Intervention: Magnetic resonance spectroscopy measurement
Description: Magnetic resonance spectroscopy measurement will be performed to measure liver fat content.
Study: NCT04605523

Intervention type: PROCEDURE
Intervention: blood withdrawal
Description: Additional blood sample will be taken within blood collection as part of standard care

Intervention type: PROCEDURE
Intervention: blood withdrawal
Description: Additional blood sample will be taken within blood collection as part of standard care
Study: NCT02036528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Study: NCT00562692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Nesiritide 4 hour infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study: NCT01526915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone curettage + PRF
Description: Bone curettage and PRF insertion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone curettage alone
Description: Bone curettage without PRF insertion
Study: NCT00164203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 12-session, weekly, school-based protocol based on cognitive restructuring, tailored to children Grades 3 to 6; comparison with activity control condition of equal duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based CBT
Description: 12 sessions, weekly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: activity control condition
Description: weekly games \& activities x 12 weeks
Study: NCT01682941

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arm I Soy Bread
Description: On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arm II Soy-Almond Bread
Description: On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
Study: NCT00006031

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle localized breast biopsy with specimen x-ray

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low dose radioactive seed followed by surgery and mammogram
Description: either iodine I 125 or palladium Pd 103
Study: NCT02116491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Sputum Suctioning System
Description: All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.